التفاصيل البيبلوغرافية
| العنوان: |
Acceptability of ‘as needed’ biologic therapy in psoriasis: insights from a multistakeholder mixed-methods study |
| المؤلفون: |
Gleeson, David, Naveed, Maneeha, Moorhead, Lucy, McAteer, Helen, Sewell, Georgia, McGuire, Arlene, Weinman, John, Barker, Jonathan N W N, Norton, Sam, Chapman, Sarah C E, Smith, Catherine H, Mahil, Satveer K |
| المساهمون: |
National Institute for Health and Care Research, Doctoral Training Fellow, NIHR Advanced Fellowship, Psoriasis Association |
| المصدر: |
British Journal of Dermatology ; ISSN 0007-0963 1365-2133 |
| بيانات النشر: |
Oxford University Press (OUP) |
| سنة النشر: |
2024 |
| الوصف: |
Background Biologic therapies have led to increasing numbers of patients with psoriasis who have clear or nearly clear skin. It is current practice to continue biologic therapy indefinitely in these patients, which contributes to a substantial long-term drug and healthcare burden. ‘As needed’ biologic therapy in psoriasis may address this; however, our understanding of patient and clinician perceptions of this strategy is limited. Objectives The aim of this mixed-methods study was to gain insight into the perspectives of both patients and clinicians regarding the acceptability of an ‘as needed’ approach to biologic therapy in psoriasis, including potential barriers and enablers to implementation in routine care. Methods We first conducted UK-wide online scoping surveys of patients with psoriasis and dermatology clinicians to explore their views on ‘as needed’ biologic therapy. Using topic guides informed by these survey findings, we then carried out qualitative focus groups with patients and clinicians. Themes were identified using reflexive thematic analysis. Results Of 67 patients and 27 clinicians completing the scoping surveys, 67% (43 of 64 patients) and 78% (21 of 27 clinicians) supported the use of ‘as needed’ biologic therapy, respectively. Respondents highlighted advantages such as a reduction in healthcare burden and greater ownership of care. Challenges included logistics of ‘as needed’ drug provision and potential risks of disease flare and drug immunogenicity. Focus groups comprised 15 patients with psoriasis [9 female patients (60%), average disease duration 32 years (range 9–64)] and 9 dermatology clinicians [8 female clinicians (89%), average dermatology experience 20 years (range 8–33)]. Both patients and clinicians felt that an ‘as needed’ treatment approach will deliver a reduction in treatment burden and present an opportunity for patient-led ownership of care. Both groups highlighted the importance of ensuring ongoing access to medication and discussing the potential impact of ... |
| نوع الوثيقة: |
article in journal/newspaper |
| اللغة: |
English |
| DOI: |
10.1093/bjd/ljae068 |
| DOI: |
10.1093/bjd/ljae068/57399669/ljae068.pdf |
| الإتاحة: |
https://doi.org/10.1093/bjd/ljae068Test |
| حقوق: |
https://creativecommons.org/licenses/by/4.0Test/ |
| رقم الانضمام: |
edsbas.DC3FAA84 |
| قاعدة البيانات: |
BASE |
